Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How sacituzumab govitecan and next-gen TROP2 ADCs are reshaping endometrial and urothelial cancer treatment — and what resistance mechanisms mean for the pipeline.
Article | Report How federated learning enables AI model training across distributed manufacturing sites without sharing raw data — architecture, privacy, and industrial deployment.
Article | Report Ifinatamab deruxtecan's DeLLphi-304 Phase III trial is redefining first-line small cell lung cancer treatment. Explore the science, patent landscape, and clinical implications.
Article | Report No verified patent or literature data was found for deterministic latency in industrial Ethernet for real-time robot control. Learn what this means for your research.
Article | Report Ulotaront, ralmitaront, and the TAAR1 agonist pipeline are reshaping schizophrenia and depression drug discovery. See the competitive landscape.
Article | Report Explore the key technical tradeoffs between hydrogen combustion and fuel cell powertrains for aviation — efficiency, weight, emissions, and integration challenges.
Article | Report Roche's trontinemab uses a transferrin receptor brain-shuttle to deliver amyloid-beta antibody at higher brain concentrations with a differentiated ARIA profile. Full Phase II analysis.
Article | Report How do model-based and data-driven fault detection methods compare for industrial rotating machinery? A technical guide for R&D and IP professionals.
Article | Report Oveporexton is the first orexin receptor agonist targeting narcolepsy type 1. Explore its FDA approval trajectory, mechanism, and competitive market dynamics.
Article | Report Key engineering challenges of building reliable humanoid robots for industrial deployment at scale — from actuator reliability to locomotion control and dexterity.
Article | Report Explore the key differences between physics-based and data-driven modeling for industrial process optimization, including hybrid approaches and when to use each.
Article | Report Tirzepatide's SURPASS-CVOT trial examines GLP-1/GIP dual agonist cardiovascular and renal outcomes in type 2 diabetes. Explore the science, IP landscape, and clinical significance.
Article | Report How do open-source and proprietary LLMs differ for enterprise R&D? Compare customisation, cost, compliance, and performance to make smarter AI deployment decisions.
Article | Report Sparsentan targets both ETA and AT1 receptors for FSGS and IgAN treatment. Explore the dual receptor antagonism mechanism, IP landscape, and clinical signals.
Article | Report IMerge Phase 3 trial: imetelstat achieved 39.8% 8-week transfusion independence vs 15% placebo in lower-risk MDS. Full pipeline analysis and biomarker data.